The clinical relevance of such a pathway has been recently confirmed in patients carrying a mutation in the IL-10R gene; these individuals exhibit defective inhibition of LPS-induced TNFα along with the early development of IBD [31]. The gene discussed is IL10RA; the disease is inflammatory bowel disease.